Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  TSX VENTURE EXCHANGE  >  Khiron Life Sciences Corp    KHRN   CA49374L3065

KHIRON LIFE SCIENCES CORP

(KHRN)
  Report  
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

Khiron Life Sciences : Provides Clarification of August 12, 2019 News Release

share with twitter share with LinkedIn share with facebook
share via e-mail
0
08/14/2019 | 09:01pm EDT

TORONTO, Aug. 14, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, wishes to clarify specific disclosure relating to the news release disseminated by the Company on August 12, 2019.

Khiron Life Sciences Corp. (CNW Group/Khiron Life Sciences Corp.)

The appointment of Tejinder Virk and Franziska Katterbach will be effective October 1, 2019.

About Khiron

Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis. The company delivers best in class regulatory compliance, has the first approved set of CBD cosmetic products on shelf in Colombia, and is currently facilitating testing to meet and surpass all license requirements for commercial cannabis derived products.

With a focused regional strategy and patient-oriented approach, the Company combines global scientific expertise, agricultural advantages, branded product market entrance experience and education to drive prescription and brand loyalty to address priority medical conditions such as chronic pain, epilepsy, depression and anxiety in the Latin American market of over 620 million people. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced executive team, and a knowledgeable Board of Directors that includes former President of Mexico, Vicente Fox

Cautionary Notes

Forward-Looking Statements

This press release may contain certain "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron's control, including the risk factors discussed in Khiron's Annual Information Form which is available on Khiron's SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.

United States Disclaimer

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

Further information in respect of the Company can be found at www.khiron.ca.

Cision
View original content to download multimedia:http://www.prnewswire.com/news-releases/khiron-provides-clarification-of-august-12-2019-news-release-300902104.html

SOURCE Khiron Life Sciences Corp.

© Canada Newswire, source Canada Newswire English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on KHIRON LIFE SCIENCES CORP
12:02aKHIRON LIFE SCIENCES : Announces DTC Eligibility, Increasing Access for U.S. Inv..
AQ
08/14KHIRON LIFE SCIENCES : Provides Clarification of August 12, 2019 News Release
AQ
08/12KHIRON LIFE SCIENCES : Boosts European Expansion With Key Executive Appointments
AQ
08/08KHIRON LIFE SCIENCES : Launches Revenue-Generating Pilot Program With Top Colomb..
AQ
08/07KHIRON LIFE SCIENCES : Signs Kuida Distribution Agreement with Grupo Éxito, Sout..
AQ
08/06DIXIE BRANDS USA : Khiron and Dixie Receive Conditional TSXV Approval for Roll-O..
AQ
08/01KHIRON LIFE SCIENCES : Provides Update on Canapalife Group Transaction
AQ
08/01KHIRON LIFE SCIENCES : Begins Pre-clinical Medical Cannabis Studies with Leading..
AQ
07/30KHIRON LIFE SCIENCES : Announces Final Approval of Acquisition of NettaGrowth
AQ
07/25KHIRON LIFE SCIENCES : Added to NYSE-Listed The Cannabis ETF
AQ
More news
Financials (CAD)
Sales 2019 10,1 M
EBIT 2019 -35,3 M
Net income 2019 -34,0 M
Finance 2019 15,5 M
Yield 2019 -
P/E ratio 2019 -5,97x
P/E ratio 2020 -14,9x
EV / Sales2019 20,4x
EV / Sales2020 4,50x
Capitalization 221 M
Chart KHIRON LIFE SCIENCES CORP
Duration : Period :
Khiron Life Sciences Corp Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 5,58  CAD
Last Close Price 1,94  CAD
Spread / Highest target 248%
Spread / Average Target 188%
Spread / Lowest Target 106%
EPS Revisions
Managers
NameTitle
Álvaro Torres Chief Executive Officer & Director
Chris Naprawa President
Sidney Samuel Himmel Chairman
Carlos Orbegozo Vice President-Operations
Darren Collins Chief Financial Officer
Sector and Competitors
1st jan.Capitalization (M$)
KHIRON LIFE SCIENCES CORP28.76%166
CANOPY GROWTH CORP1.75%9 336
AURORA CANNABIS INC16.67%5 988
BEIJING TONGRENTANG CO., LTD.1.02%5 485
CRONOS GROUP INC12.10%4 015
CURALEAF HOLDINGS INC39.32%3 185